Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

By sjmartinez • February 19, 2024

Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, Trukhin D, Hochmair MJ, Özgüroğlu M, Ji JH, Statsenko G, Conev N, Bondarenko I, Havel L, Losonczy G, Xie M, Lai Z, Godin-Heymann N, Mann H, Jiang H, Shrestha Y, Goldman JW. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 Feb 16;30(4):824-835. doi: 10.1158/1078-0432.CCR-23-1689. PMID: 37801329; PMCID: PMC10870117.

Tags: Hematology/Oncology, Publications

Related Posts

The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer

Cecchini M, Han SW, Lee S, Lee KW, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao[...]

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]

Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

Chen X, Mao Z, Kolawole EM, Persechino M, Jude KM, Ogishi M, Mo KC, McLaughlin J, Cheng D, Xiang X, Yang X, Gee C, Liu[...]